Linked Life Data

16092095

Source:http://linkedlifedata.com/resource/pubmed/id/16092095

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-8-15
pubmed:abstractText
Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0885-3185
pubmed:author
pubmed:copyrightInfo
Copyright 2005 Movement Disorder Society.
pubmed:issnType
Print
pubmed:volume
20 Suppl 12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S77-82
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Treatment of dementia with Lewy bodies and Parkinson's disease dementia.
pubmed:affiliation
Department of Neurology, Medical University of Innsbruck, Austria. werner.poewe@uibk.ac.at
pubmed:publicationType
Journal Article